Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
InnoCan Pharma: Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
26 Leser
Artikel bewerten:
(0)

Research and Markets - Global Cardiac Resynchronization Therapy Defibrillator Market CAGR Growth of 8.36% by 2020 - Trends, Technologies & Opportunities Report 2016-2020 - Key Vendors: St Jude Medical, Cook Medical, Spectranetics

DUBLIN, July 6, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Cardiac Resynchronization Therapy Defibrillator Market 2016-2020" report to their offering.

The report forecasts the global cardiac resynchronization therapy defibrillator (CRT-D) market to grow at a CAGR of 8.36% during the period 2016-2020.

Commenting on the report, an analyst from the research team said: One trend that will boost the market is the growing popularity of robotic-assistance surgery. Robotic surgery is rapidly evolving and also successfully investigated for the implantation of CRT-D in patients. In few instances, the manual implantation of CRT-D may not be possible due to anatomic limitations. The introduction of robotic systems is one of the noteworthy advancements in minimally invasive cardiac surgeries. Robotic technology provides physicians with an excellent view of the operative field and the ability to manoeuvre instruments within close-fitting spaces with precision and control. Robotic surgical procedures help to reduce patients' hospital stays and facilitate better cost management.

According to the report, a key growth driver is clinical considerations to make a switch to CRT-D technology. The switching from CRT-P to CRT-D, owing to clinical considerations, will propel the market growth. Clinical research studies show that CRT-D devices can reduce re-admissions to hospital for individuals with heart failure. In people with ischaemic cardiomyopathy or ischemic etiology, CRT-D implantation has showed better survival rate than CRT-P devices. There are incremental benefits in CRT-D devices compared to CRT-P devices, as it reduces the risk of sudden cardiac death (SCD) and improves the left ventricular function.

Questions Answered:

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Companies Mentioned:

  • Boston Scientific
  • LivaNova
  • Medtronic
  • St. Jude Medical
  • BIOTRONIK
  • Cook Medical
  • Spectranetics

Report Structure:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Cost analysis of CRT-D device implantation

PART 06: Market landscape

PART 07: Geographical segmentation

PART 08: Market drivers

PART 09: Impact of drivers

PART 10: Market challenges

PART 11: Impact of drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Appendix

PART 15: About the Author

For more information visit http://www.researchandmarkets.com/research/2xckjp/global_cardiac

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.